Avidity Biosciences’ RNA therapy for facioscapulohumeral muscular dystrophy has preliminary clinical data showing it knocked down expression of a gene that causes this rare disease. More details will be presented at a medical conference this week.

The post Avidity Bio’s RNA Therapy Flashes Early Signs of Treating a Muscular Dystrophy’s Root Cause appeared first on MedCity News.

Sarah Boyce knows she is a rare breed – a female biotech CEO. In this episode, Boyce talks about the novel therapy she is trying to develop to tackle a rare genetic muscle condition, while also building a company that is committed to diversity and inclusion.

The post MedCity Pivot Podcast: How a female biotech CEO is developing a novel therapy while committing to a diverse workforce appeared first on MedCity News.